Stock Price, News, Quote and Profile of VOR BIOPHARMA INC(NASDAQ:VOR) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

VOR BIOPHARMA INC

NASDAQ:VOR (4/29/2024, 7:00:03 PM)

After market: 1.76 +0.02 (+1.15%)

1.74

+0.05 (+2.96%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap118.70M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 133 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. The company is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of VOR33 in participants with AML.

Company Info

VOR BIOPHARMA INC

100 Cambridgepark Drive, Suite 101

Cambridge MASSACHUSETTS

P: 16176556580

Employees: 133

Website: https://www.vorbio.com/

VOR News

a month ago - Vor BiopharmaVor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...